Inventiva S.A. announces abstracts for AASLD meeting
- Presented three abstracts at AASLD The Liver Meeting 2026
- Preclinical data showed lanifibranor affects multiple hepatic cell pathways
- Phase 3 trial results expected in Q4 2026
Every EDGAR filing for Inventiva S.A. (IVEVF), newest first, with AI summaries and stories.
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Securities offering
Ownership stake disclosure by Deep Track Capital, LP (amended)
Deep Track Capital, LP, filed by
Ownership stake disclosure by New Enterprise Associates 17, L.P. (amended)
New Enterprise Associates 17, L.P., filed by
Ownership stake disclosure by Andera Partners (amended)
Andera Partners, filed by
Ownership stake disclosure by Crossover I Sofinnova (amended)
Crossover I Sofinnova, filed by
Ownership stake disclosure by EVENTIDE ASSET MANAGEMENT, LLC (amended)
EVENTIDE ASSET MANAGEMENT, LLC, filed by
Ownership stake disclosure by Deep Track Capital, LP
Deep Track Capital, LP, filed by
Samsara BioCapital, L.P., filed by
BIOTECHNOLOGY VALUE FUND L P, filed by
Ownership stake disclosure by PERCEPTIVE ADVISORS LLC (amended)
PERCEPTIVE ADVISORS LLC, filed by
Ownership stake disclosure by GREAT POINT PARTNERS LLC (amended)
GREAT POINT PARTNERS LLC, filed by
Yiheng Capital Management, L.P., filed by